Arena Pharmaceuticals

Clinical-stage biotech focused on cardiovascular, central nervous system, inflammatory and metabolic diseases. Their leading drug candidate is lorcaserin hydrochloride, which recently received positive data from a clinical trial. They are headquartered in San Diego, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arena Pharmaceuticals, Inc. (ARNA) reported earnings 30 days ago. What's next for the stock?

Arena Pharmaceuticals, Inc. (ARNA) Down 12.2% Since Last Earnings Report: Can It Rebound?

Can this pharma blow past its highs from 10 years ago, or will it fade away -- again?

3 Reasons to Avoid Arena Pharmaceuticals -- and 1 Reason to Buy

British American Tobacco

HEXO Corp

Innovative Industrial Properties

Akerna Corp

OrganiGram Holdings Inc.

Tilray Brands

cbdMD Inc

Zynerba Pharmaceuticals

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will continue to develop in the 2021.

8 Cannabis Stocks on Fire After Corporate Moves

Greenlane Holdings

New Age Beverages

22nd Century Group

4 Cannabis Stocks in the News This Week

Arena's (ARNA) mid-stage study evaluating olorinab in patients with abdominal pain due to irritable bowel syndrome fails to meet primary endpoint.

Arena (ARNA) Tumbles as Mid-Stage Gastrointestinal Study Fails

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ArenaPharm--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced topline results from the randomized, double-blind, placebo-controlled Phase 2b CAPTIVATE clinical trial evaluating three doses of olorinab, a novel, oral, peripherally acting, highly selective, full agonist of the cannabinoid receptor 2 (CB2), in participants with abdominal pain due to Irritable Bowel Syndrome (IBS). The CAPTIVATE trial randomized a total of 273 participants and was conducted in study s

Arena Pharmaceuticals Reports Topline Results from Phase 2b CAPTIVATE Clinical Trial

Aphria

Jazz Pharmaceuticals

SNDL Inc.

Village Farms International

Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will continue to develop in the 2021.

8 Red-Hot Pot Stocks Toughing Out Last Week's Winter Weather

Arena Pharmaceuticals (ARNA) misses bottom-line estimates for fourth-quarter 2020. It initiates new study to evaluate etrasimod in patients with eosinophilic esophagitis.

Arena (ARNA) Q4 Earnings Miss Estimates, Pipeline Progresses

Arena Pharmaceuticals Inc.'s (ARNA) CEO Amit Munshi on Q4 2020 Results - Earnings Call Transcript

Shares of Arena Pharmaceuticals (NASDAQ:ARNA) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 19.32% year over year to ($2.10), which missed the estimate of ($1.85).

Recap: Arena Pharmaceuticals Q4 Earnings

SAN DIEGO--(BUSINESS WIRE)---- $ARNA #ArenaPharm--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2020. “This quarter we were pleased to announce the completion of enrollment of the ELEVATE UC 52 trial for etrasimod and expansion of our cardiovascular franchise to include temanogrel. Our growing and diverse pipeline is supported by a strong cash position,” said Amit D. Munshi, President and CEO of Aren

Arena Reports Fourth Quarter Financial Results with Strong Liquidity Position and Maintained Pipeline Progress Over the Quarter

On Tuesday, February 23, Arena Pharmaceuticals (NASDAQ:ARNA) will release its latest earnings report. Check out Benzinga's preview to understand the implications.

Arena Pharmaceuticals Earnings Preview

Canopy Growth

GW Pharmaceuticals

9 Red-Hot Cannabis Stocks Blazing This Week

SAN DIEGO--(BUSINESS WIRE)---- $ARNA #earnings--Arena Pharmaceuticals to Release Fourth Quarter & Full-Year 2020 Financial Results and Provide Corporate Update on February 23.

Arena Pharmaceuticals to Release Fourth Quarter & Full-Year 2020 Financial Results and Provide Corporate Update on February 23

SAN DIEGO--(BUSINESS WIRE)-- #ArenaPharm--Industry veteran Garry Neil, MD named Board Chair. Nawal Ouzren, CEO of Sensorion named to Board.

Arena Pharmaceuticals Announces Changes to Board of Directors

SAN DIEGO--(BUSINESS WIRE)---- $ARNA--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has completed full enrollment of the Phase 3 ELEVATE UC 52 trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in participants with moderately-to-severely active ulcerative colitis. The trial enrolled 433 study participants in approximately 40 countries globally. “Completion of UC 52 enrollment is the first impor

Arena Pharmaceuticals Completes Full Enrollment of Etrasimod Phase 3 ELEVATE UC 52 Trial

Aurora Cannabis

FSD Pharma

Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will develop in the 2021.

8 Pot Stocks in Focus Amid the WallStreetBets Frenzy

Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks over the past week, and look ahead to how the cannabis industry will develop in the new year.

Six Marijuana Stocks Stay Hot During a Short Week

Molson Coors Brewing

9 Cannabis Stocks Heating Up Headlines This Week

Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi Presents at 39th Annual J.P. Morgan Healthcare Conference (Transcript)

SAN DIEGO, Dec. 22, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, is scheduled to present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13,...

Arena Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 13

SAN DIEGO, Dec. 11, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from the Phase 2b ADVISE trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in...

Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial - Late-Breaker at Revolutionizing Atopic Dermatitis Conference

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead at the pot stocks to watch in the upcoming week.

This Week in Cannabis: 6 Stocks Pivoting for Serious Growth

Evercore

Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi Presents at 3rd Annual Evercore ISI HealthCONx Conference (Transcript)

SAN DIEGO--(BUSINESS WIRE)--Arena Pharmaceuticals announces the appointment of Paul D. Streck, M.D., as Senior Vice President, Clinical Development and Chief Medical Officer.

News for Arena Pharmaceuticals Stock (ARNA)